SLGL - יחס חוב להיוון בספרים Sol-Gel Technologies Ltd

Sol-Gel Technologies (SLGL) delegates production and testing to external contractors, creating a dependency on their stability. The company's debt load relative to its balance sheet capital illustrates its financial resilience, where the value of 0.02 reflects this status. Revenues are based on the sale of innovative treatments for rosacea and acne. The technology licensing model ensures royalty scalability, effectively protecting the net margin.

For Sol-Gel Technologies (SLGL), which is developing a microencapsulation ecosystem for dermatological products, the ratio of financial leverage to balance sheet capital serves as an indicator of the company's financial stability. This metric compares total credit obligations against the market value of the enterprise's own assets. The calculation allows for an assessment of the business's ability to cover debts in the event of a hypothetical decline in revenue. A steady influx of patients through partnerships mitigates borrowing risks, while a low ratio confirms solvency during the expansion of formulations.